Success Metrics

Clinical Success Rate
100.0%

Based on 21 completed trials

Completion Rate
100%(21/21)
Active Trials
0(0%)
Results Posted
33%(7 trials)

Phase Distribution

Ph phase_4
3
14%
Ph phase_3
4
19%

Phase Distribution

0

Early Stage

0

Mid Stage

7

Late Stage

Phase Distribution7 total trials
Phase 3Large-scale testing
4(57.1%)
Phase 4Post-market surveillance
3(42.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

21 of 21 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

21

all time

Status Distribution
Completed(21)

Detailed Status

Completed21

Development Timeline

Analytics

Development Status

Total Trials
21
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 34 (57.1%)
Phase 43 (42.9%)

Trials by Status

completed21100%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT05511038Phase 4

A Study to Learn How Safe the Study Drug Intravitreal (Given by an Injection Into the Eye) Aflibercept is in Participants in India With Diabetic Macular Edema

Completed
NCT02305238Phase 4

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

Completed
NCT01783925

Eylea Post Marketing Surveillance(PMS)

Completed
NCT02289924

Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy

Completed
NCT02279537

Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD

Completed
NCT02924311

Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema

Completed
NCT04524910

A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV)

Completed
NCT04641234

A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).

Completed
NCT02540954Phase 3

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Completed
NCT02120950Phase 4

Aflibercept in Polypoidal Choroidal Vasculopathy

Completed
NCT02818998Phase 3

Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)

Completed
NCT02260687

Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Completed
NCT02811692

Study for Collection of Aflibercept Data in Routine Practice

Completed
NCT02040220

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)

Completed
NCT02540369

To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.

Completed
NCT01756261

EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan

Completed
NCT01914380

Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration

Completed
NCT02615496

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

Completed
NCT02541084

Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

Completed
NCT01482910Phase 3

VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
21